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Abstract
Background: Cervical cancer is the second most common cause of cancer deaths in women worldwide. The aim
of this study is to exploit novel pathogenic genes in cervical carcinogenesis.
Method: The somatic mutations from 194 patients with cervical cancer were obtained from the Cancer Genome
Atlas (TCGA) publically accessible exome-sequencing database. We investigated mutated gene enrichment in the
12 cancer core pathways and predicted possible post-translational modifications. Additionally, we predicted the
impact of mutations by scores quantifying the deleterious effects of the mutations. We also examined the
immunogenicity of the mutations based on the mutant peptides’ strong binding with major histocompatibility
complex class I molecules (MHC-I). The Kaplan-Meier method was used for the survival analysis.
Results: We observed that the chromatin modification pathway was significantly mutated across all clinical stages.
Among the mutated genes involved in this pathway, we observed that the histone modification regulators were
primarily mutated. Interestingly, of the 197 mutations in the 26 epigenetic regulators in this pathway, 25 missense
mutations in 13 genes were predicted in or around the phosphorylation sites. Only mutations in the histone
methyltransferase MLL2 exhibited poor survival. Compared to other mutations in MLL2 mutant patients, we noticed
that the mutational scores prioritized mutations in MLL2, which indicates that it is more likely to have deleterious
effects to the human genome. Around half of all of the mutations were found to bind strongly to MHC-I, suggesting
that patients are likely to benefit from immunotherapy.
Conclusions: Our results highlight the emerging role of mutations in epigenetic regulators, particularly MLL2, in
cervical carcinogenesis, which suggests a potential disruption of histone modifications. These data have implications
for further investigation of the mechanism of epigenetic dysregulation and for treatment of cervical cancer.
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Background
Cervical cancer remains a serious global health problem,
with an estimated 528,000 new cases and 266,000 deaths
in 2012 [1]. Approximately 80% of cervical cancers occur
in developing countries [2]. Certain types of the human
papilloma virus (HPV) infection, particularly HPV 16
and HPV 18, are the greatest risk factors for cervical
cancer. Screenings, such as the Papanicolaou and HPV
tests, have been largely successful in preventing cervical
cancer, but it is still the second most common cause of
cancer death among women worldwide, resulting in
275,000 deaths annually [3].
Not all individuals who are infected with high-risk
HPVs develop genital cancer, which indicates that HPV
infection is necessary but not sufficient for malignant
development [4–6]. Additional genetic alterations, either
independent or in conjunction with HPV infection, are
required for tumor development. When cells are persist-
ently infected with HPV, the primary viral oncoproteins
E6 and E7 are reportedly involved in the disruption of
many normal functions [7–10]. Consequently, these lead
to an accumulation of somatic mutations. Early reports
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have frequently observed somatic mutations in cervical can-
cer [11, 12]. These genetic alterations can be equally import-
ant for cell transformation. An in-depth characterization of
the underlying genetic events is important for understanding
tumor progression, which can guide the development
of effective targeted therapies.
The large volume of data currently generated by the
TCGA provides a rich resource and a new opportunity
for exploring the genetic alterations in cervical cancer.
In this study, we set out to explore the pathogenic genes
by investigating the somatic mutations in 194 cases of
cervical cancer exome-seq data from the TCGA. The
analysis showed that the chromatin modification path-
way was significantly altered. Half of the epigenetic regu-
lators involved in this pathway harbored mutations
capable of disrupting the phosphorylation sites. Of all of
the altered epigenetic regulators, only the histone meth-
yltransferase MLL2 mutations were associated with poor
survival. Around half of the mutations’ peptides were
predicted to be immunoreactive, which indicates that
patients are likely to benefit from immunotherapy. This
study highlights the emerging role of epigenetic regula-
tors, particularly MLL2, and suggests potential epigen-
etic dysregulation, in cervical cancer tumorigenesis.
Methods
Data and preprocessing
The processed exome-seq mutation data and clinical in-
formation for all patients in this study were downloaded
from TCGA (“Level 2” data designation). We filtered out
variants located in the 1000 Genome Project (Phase 3)
[13], and the NHLBI GO Exome Sequencing Project
(version 2) [14], which represented more than 200,000
individuals’ variants, and the Exome Aggregation Con-
sortium (version 0.2) [15], which spanned 60,706 unre-
lated individuals’ variants by applying a minor allele
frequency threshold of 0.1 to all three databases. Vari-
ants were annotated with the variant effector predictor
tool [16]. Only the nonsynonymous mutations then
remained. The annotated genes harboring each of non-
synonymous mutations were remained as mutated genes.
All further analyses were based on these nonsynon-
ymous mutations and mutated genes.
Pearson correlation was used to assess the correlation
between the number of somatic and nonsynonymous
mutations in each clinical stage. The difference in the
number of nonsynonymous mutations in early stages (I
and II) and later stages (III and IV) was performed by
two-sided Student’s t test. P value less than 0.05 was
considered to indicate statistical significance.
Driver genes and core pathways collection
The 138 driver genes and 12 core cancer pathways were
obtained from a previous report [17]. In general, a total
of 18,306 mutated genes harboring 404,863 subtle muta-
tions from the Catalogue of Somatic Mutations in
Cancer (COSMIC) database [18] were assessed as driver
genes, and it was determined whether each gene was
likely to be an oncogene or tumor suppressor gene. The
gene was classified as an oncogene if >20% of the re-
corded mutations in the gene occurred at recurrent
positions and were missense. The gene was categorized
as a tumor suppressor gene if >20% of the recorded
mutations in the gene were inactivating. This “20/20
rule” [17] was applied to the selection of the 138 driver
genes. These driver genes were classified into 12 signal-
ing pathways regulating three core cellular processes:
cell fate, cell survival, and genome maintenance [17].
Pathway enrichment analysis
To quantify the association between the mutated genes
in cervical cancer and the 12 core pathways, we down-
loaded the cancer-associated genes from the COSMIC
database. Then, for each stage, we calculated the total
number of non-redundant genes in COSMIC, the total
number of non-redundant mutated genes in the corre-
sponding stage, the number of genes in COSMIC that
was found in each core pathway, and the number of
mutated genes in each stage that was also found in each
core pathway. The representation of each of the core
pathway genes within the mutated genes in each stage
was compared to the representation of those within all
of the genes in the COSMIC database using Fisher’s
exact test, similar to a previous approach [19]. The
adjusted p value for each pathway was calculated using
the Benjamini and Hochberg method. The significantly
enriched pathway was considered if the adjusted p value
was below 0.025.
Post-translational modifications prediction
The missense mutations of all of the epigenetic regulators
were extracted from the output of the variant effector pre-
dictor. For each epigenetic regulator, the mutant amino
acid sequence was extracted from the corresponding wild-
type amino acid sequence, with the mutated position
substituted with the mutated residue. The paired wild-
type sequence and the mutant sequence for each gene
were constructed in a Fasta format. The ReKINect tool
[20] was used to predict the likely functionality for each
mutation.
The protein domains were derived from Uniprot. IBS
software [21] was used to illustrate the protein domain
structure and the amino acid changes.
Immunogenic variants prediction
For each somatic point mutation, we obtained the corre-
sponding mutated amino acid and constructed one pep-
tide centered on the mutated residue, which was flanked
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on each side by eight amino acids from the protein se-
quence. We also obtained the corresponding normal
17-amino-acid peptide. The NETMHC-3.4 algorithm
[22] was used to predict the binding affinity for the
mutant peptide and the normal peptide with MHC-I,
separately. For each mutant or normal 17-amino acid
peptide, a peptide of length 9 was used to predict its
binding affinity with MHC-I. The mutation exhibited
immunogenicity only if the mutant peptide showed a
strong binding affinity with MHC-I (affinity value <50)
and the normal peptide had no binding affinity (affinity
value >500) at the same peptide position.
Mutational score calculation
Based on the nonsynonymous mutations of patients
harboring MLL2 mutations, we predicted the deleterious
effects for each mutation in each patient by calculating a
mutational score. Using a previously published strategy
[23], each mutation was assigned a score that quantified
its deleterious impact by integrating multiple factors, such
as functional genomic data, transcription factor binding,
transcript information, and protein level information. In
general, a higher score indicates that a mutation is more
likely to have deleterious effects. A gene’s mutational score
was calculated by summing the scores of all the mutations
found in the gene.
Survival analysis
Survival curves were generated using the Kaplan-Meier
method, and differences were evaluated using the Log-
rank (Mantel-Cox) test. Overall survival was calculated
from the time of initial diagnosis to death, or censored
to the time when the patient was last known to be alive.
P values under 0.05 were considered statistically signifi-
cant. Hazard ratios and associated 95% confidence inter-
vals were calculated with the Cox proportional-hazards
model. All tests were two-sided and all calculations were
performed with the R Version 3.1.1 statistical software.
Results
Patient data and somatic mutations
We collected exome-seq data for 194 cases. According
to the International Federation of Gynecology and Ob-
stetrics (FIGO) staging system [24], 121 patients had
Stage I disease, 36 Stage II, 30 Stage III, and 7 Stage IV.
After filtration, we obtained a total of 37,317 somatic
mutations. We annotated these mutations, and 25,742
nonsynonymous mutations were used for downstream
analyses. All of the mutated genes and nonsynonymous
mutations are listed in Additional file 1: Table S1. We
observed a strong correlation between the number of
somatic and nonsynonymous mutations in each clinical
stage (Additional file 2: Figure S1). Although we ob-
served that the later stages (III and IV) exhibited higher
incidences of nonsynonymous mutations than the early
stages (I and II), the number of nonsynonymous muta-
tions showed no significant correlation with the patients’
clinical stage (Student’s t test, p value: 0.4781; Additional
file 3: Figure S2).
The chromatin modification pathway is the most
significantly altered
Of the approximately 20,000 protein-coding genes in the
human genome, only 138 driver genes were reported and
classified into 12 core pathways [17] (Additional file 4:
Table S2). We researched whether these driver genes had
been reported in another well-known cancer driver gene
database, IntOgen [25]. Most of them (71%) had been
detected as mutational cancer drivers (Additional file 4:
Table S2). Using the 138 driver genes obtained from a pre-
vious report [17], we examined their mutations in our
data. Of the 25,742 nonsynonymous mutations, a total of
105 driver genes of them harbored 491 mutations
(Additional file 5: Table S3).
Because these driver genes and core pathways play sig-
nificant roles in tumorigenesis, we determined whether
any of these pathways were significantly altered. All of
the nonsynonymous mutations in all stages were inte-
grated, and the pathway enrichment analysis revealed
that the chromatin modification pathway was the most
significantly altered across all stages, particularly at Stages
II and IV (Fisher’s exact test, adjusted p value: 0.010344
(Stage I), adjusted p value: 2.8176e-6 (Stage II), adjusted
p value: 7.1292e-3 (Stage III), adjusted p value: 7.0056e-4
(Stage IV); Fig. 1). At Stage I, the RAS (Fisher’s exact test,
adjusted p value: 0.010344; Fig. 1) and PI3K (Fisher’s exact
test, adjusted p value: 0.0245; Fig. 1) pathways were found
to be significantly altered. The PI3K pathway was also sig-
nificantly mutated at Stage III (Fisher’s exact test, adjusted
p value: 0.020184; Fig. 1). The NOTCH (Fisher’s exact test,
adjusted p value: 0.020184; Fig. 1) and apoptosis (Fisher’s
exact test, adjusted p value: 0.020184; Fig. 1) pathways
were also significantly altered at Stage III. Thus, the chro-
matin modification pathway dominated across all tumor
stages.
The mutated genes involved in these pathways are il-
lustrated in Fig. 2 and Additional file 6: Figure S3. In the
chromatin modification pathway, recurrent mutations in
MLL3, EP300, MLL2, ARID1A, and CREBBP were
present in 12%, 11%, 8%, 7%, and 7% of patients, re-
spectively (Fig. 2). EP300 was most recurrently mutated
in the NOTCH pathway (11%), followed by FBXW7 (9%)
(Additional file 6: Figure S3). NFE2L2 was recurrently mu-
tated in the apoptosis pathway (6%) and ERBB2 in the
RAS pathway (5%) (Additional file 6: Figure S3). PIK3CA
(9%), and ERBB2 (5%) were recurrently mutated in the
PI3K pathway (Additional file 6: Figure S3). Furthermore,
EP300, ARID1A, FBXW7, NFE2L2, PIK3CA, and ERBB2
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have all been previously reported as pathogenic genes in
cervical cancer [11, 12], and we highlighted the roles of
MLL2,MLL3, and CREBBP in the tumorigenesis.
Histone modification regulators are mainly mutated
After carefully observing the recurrently altered genes
involved in the chromatin modification pathway (Fig. 2),
it was clear that the histone modification regulators were
primarily mutated. MLL3 and MLL2 both serve as en-
zymes in histone lysine methyl-transferation. Mutations
in MLL2 have been shown to be a cause of Kabuki syn-
drome [26]. One stop-gained mutation at residual
Q5248 and one missense mutation at D5279 occurred in
the FYR C-terminal domain, which is required to adopt
an alpha + beta fold. Another missense mutation,
p.D5462H, occurred in the SET domain that serves a
function in lysine methyl-transferation (Fig. 3). The mu-
tations occurring in these domains were different from
those observed in Kabuki syndrome [26]. EP300, which
was previously identified to be recurrently mutated in
cervical cancer [11], has a high sequence similarity to
CREBBP. Both were determined to harbor recurrent
mutations in the CBP/p300-type HAT domain, which
functions as a histone acetyl-transferation (Fig. 3). In
SETD2, also a histone methyltransferase, a mutation
p.Q1619E occurred at the SET domain, which also causes
lysine methyl-transferation (Fig. 3). Thus, mutations oc-
curring in these regulators may lead to abnormal enzyme
activities, such as aberrant histone methylations.
Interestingly, of the 197 mutations in the 26 epigenetic
regulators involved in the chromatin modification path-
way, 25 missense mutations in 13 genes were predicted
in or around the phosphorylation sites (Fig. 3; Additional
file 7: Figure S4; Additional file 8: Table S4). Phosphoryl-
ation is an important post-translational modification that
is capable of activating or inhibiting the activity of proteins
in numerous biological processes [27, 28]. Mutations that
destroy the phosphorylation sites may consequently
Fig. 1 The chromatin modification pathway was the most significantly altered. Bar plots show the predefined core cancer pathways’ [17] enrichment
of the mutated genes at each clinical stage. The bar plot in red, blue, orange, and purple represents Stage I, Stage II, Stage III, and Stage IV, respectively.
The Fisher’s exact test was performed to calculate the p value. The adjusted p value for each pathway was calculated using the Benjamini and
Hochberg method. The logarithm transformation (base 10) was applied to the adjusted p value. Vertical red line represents the cut-off of the adjusted
p value of 0.025
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disturb the signaling transduction network in the cell or
affect their enzymatic activities.
Mutations in MLL2 are associated with worse survival
We next ask whether these epigenetic regulator muta-
tions affected patients’ survival. Of the mutated genes,
patients with MLL2 mutations exhibited a worse overall
survival rate than those without (hazard ratio = 0.3912;
95% confidence interval, 0.1864 to 0.8212; p value:
0.0101; Fig. 4a). A risk of death reduction of around 61%
was observed in those without MLL2 mutations. No dif-
ferences were observed in patients with and without either
of the epigenetic regulatory gene mutations (Log-rank
Mantel-Cox, p value: 0.131). Thus, MLL2 may be a prog-
nostic factor. We tested other recurrent genes in the
PI3K, RAS, Apoptosis, and NOTCH pathways, including
PIK3CA, ERBB2, NFE2L2, and FBXW7. Interestingly,
though these genes were previously reported as patho-
genic in cervical cancer, only patients harboring mutant
ERBB2 displayed poorer overall survival than those with
wild-type (hazard ratio = 0.2864; 95% confidence interval,
0.12 to 0.6836; p value: 0.0027; Fig. 4b). ERBB2 was
involved in both the PI3K and RAS pathways. No dif-
ferences were observed in patients with and without
either of the mutations in these two pathways. There-
fore, our data showed that, along with the previously
reported pathogenic genes, mutations in MLL2 also
exhibited a new prognostic characteristic in cervical
cancer.
The impact of mutations in MLL2
In addition, based on the mutation spectrum in the
patients harboring MLL2 mutations in our study, we
predicted the impact of their mutations by quantifying
the deleterious effects of the mutations. In general, this
strategy scored each mutation by considering many fac-
tors, such as functional genomic data, transcription factor
binding, transcript information, and protein level informa-
tion [23], with a higher score indicating that a mutation is
more likely to have deleterious effects. Among 17 patients
in our data, we display here the scores of mutations in
MLL2 in 13 patients (76.5%), which is ranked in the top
10 mutated genes. In three patients,MLL2 had the highest
mutational score as compared to the majority of the other
mutated genes in each patient (Fig. 5). It is highly probable
that the mutations in MLL2 could have deleterious effects
to the human genome.
The immunogenicity of mutations suggests potential
immunotherapy
In malignant tumors harboring mutations, some of the
mutations may generate “non-self” neo-antigens. These
neo-epitopes, if presented to the cell surface through the





























Fig. 2 Mutated genes involved in the chromatin modification pathway. The heatmap shows the distribution of the mutated genes involved in
the chromatin modification pathway across all clinical stages. Each column represents an individual, and each row denotes a gene. The bar graph
on the top shows the Stage I, Stage II, Stage III, and Stage IV patient subgroups as red, blue, orange, and purple, respectively. The bar plots on the
right side show the mutation frequency of each gene in each clinical stage colored by the stages
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surface, could be recognized by the immune system such
as T lymphocytes. Those tumor cells could then be im-
munoreactive as an anti-tumor response could be trig-
gered. The recent neo-antigen identification approach is
based on somatic point mutation by predicting the
binding affinity between the mutated peptide and MHC-I,
which indicates that immunotherapy may be a promising
new treatment [29–33].
We examined all of the mutations’ immunogenicity by
predicting their derived mutant peptides and their

























































Fig. 4 Overall survival of patients. Kaplan-Meier analysis of the survival of patients with and without MLL2 (n = 194; 17 MLL2 mt and 177 MLL2 wt
patients) (a), or ERBB2 (n = 194; 10 ERBB2 mt and 184 ERBB2 wt patients) (b) mutations. Differences were evaluated by the Log-rank (Mantel-Cox)





























































































































































































































































































































































































Fig. 3 Recurrently mutated histone modification regulators harboring mutations destroying phosphorylation sites. EP300, MLL2, ARID1A, CREBBP,
and SETD2 are shown in the context of protein domain models derived from UniProt. Each filled circle represents a mutated patient. Somatic
missense mutations destroying the phosphorylation sites are marked in red. Domains are depicted with various colors
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corresponding normal peptides’ binding affinities with
MHC-I. On average, around 50% of the total variants’
peptides showed strong binding with MHC-I across all
stages (Fig. 6a), while the corresponding normal peptides
had no binding affinity at the same peptide position.
This indicated that tumor cells in each stage can gener-
ate neo-epitopes that may induce an anti-tumor immune
response. Moreover, we also observed marginal associ-
ation between the number of neo-epitopes and patient
survival (hazard ratio = 2.5185; 95% confidence interval,
0.9957 to 6.37; p value: 0.0437; Fig. 6b). Therefore,
cervical cancer patients are likely to benefit from
immunotherapy.
Discussion
Papanicolaou smear and colposcopy programs can pre-
vent cervical cancer development; however, 80% of diag-
nosed cases have already progressed to the later stages
[34]. Women with cervical cancer remain a high-risk
population for whom effective treatment options and re-
liable therapy targets are limited. In this study, we dem-
onstrated that the chromatin modification pathways of
cervical cancer patients were significantly altered. Muta-
tions in MLL2, a histone methyltransferase, were associ-
ated with poor survival. This study indicates that genetic
mutations in epigenetic regulators and potential epigenetic
dysregulation play a role in the development of cervical
cancer. As a result, our understanding of the pathogenesis
of cervical cancer is greatly improved, and new thera-
peutic strategies are suggested.
Aberrant epigenetic changes in cervical cancer have
been widely studied, and the main focus has been on
DNA methylation [35–37], such as the hypermethylation
of oncogenic genes [35]. In contrast, histone modifica-
tion changes in cervical cancer have not been studied as
extensively. Alterations of epigenetically modified genes
were not examined in our study, but it was shown that
epigenetic regulator genes were actually recurrently mu-
tated in cervical cancer. It was also shown that they
mainly had a histone methyl-transferation function. Thus,
the mutation of these factors may consequently lead to ab-


























































































































































































Fig. 5 Mutational scores of MLL2 mutations. For each nonsynonymous
mutation in each patient harboring mutant MLL2, a mutational score
was calculated as described previously [23]. A gene’s mutational score
was calculated as the sum of all the scores of the mutations found
































































Fig. 6 Percentage of neo-epitopes across stages and association with survival. a A violin plot shows the distribution of neo-epitopes percentage
at each clinical stage. The neo-epitope percentage was calculated by dividing the total number of neo-epitopes by the total number of variants
in each patient. b Overall survival for patients based on the neo-epitope number. Kaplan-Meier curves were constructed to look at the difference
in the survival of patients with high and low numbers of neo-epitopes. Patients in the top 1/4 neo-epitope number were chosen as patients with
high neo-epitope count, and the bottom 1/4 were chosen as the low neo-epitope count. Differences were evaluated by the Log-rank (Mantel-Cox) test
(n = 95; 47 high neo-epitope count and 48 low neo-epitope count patients)
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mutations in the histone methyltransferase MLL2 that
methylates the Lys-4 position of histone H3 exhibited
worse overall survival. It is highly probable that the cer-
vical cancer genome may harbor abnormal H3K4 methy-
lation, which may shape a new epigenetic landscape that
contributes to cancer deterioration. Approaches such as
Chromatin immunoprecipitation (ChIP) followed by
high-throughput DNA sequencing (ChIP-seq) for the
H3K4me3, and other histone modifications in the
patient tissues, deserve further study.
Half of the epigenetic regulators harbored mutations
in or around the phosphorylation sites in their enzymes.
Interestingly, the blocking of EP300’s phosphorylation
was reported to decrease the proliferation and metastasis
activity of lung cancer cells. The molecular mechanism
showed that phosphorylation blocking in this protein
disrupted chromatin condensation and increased the
acetylation of histone H3 [38]. The phosphorylation of
MLL2, controlled by CDK2, facilitated its recruitment to
developmental genes in G1 in human pluripotent cells,
consequently leading to changes in the developmental
genes’ chromosome architecture [39]. Mutations occur-
ring on the phosphorylation site in CREBBP were shown
to result in inappropriate activation of gluconeogenesis
[40]. The inhibition of SETD2’s phosphorylation by long
non-coding RNA HOTAIR has been reported to trigger
a reduction of trimethylation on histone H3 thirty-sixth
lysine, consequently promoting human liver cancer stem
cell malignant growth [41]. SMARCA4, also known as
BRG1, was shown to modulate DNA double-strand
break repair by its phosphorylation [42]. It has been sug-
gested that the enzymatic activity of DNMT1 is possibly
modulated by phosphorylation [43], and it has been
demonstrated that its phosphorylation by AKT1 kinase
increases its stability and abundance [15]. The phosphor-
ylation of NCOR1 was shown to play a role in transcrip-
tional regulation in prostate cancer [44] and in the liver
in mice [45]. EZH2, despite of its ability to trimethylate
lysine 27 in histone H3, when phosphorylated, suppressed
its methyltransferase activity [46, 47], and switched to a
coactivator for its oncogenic function in prostate cancer
[48]. The phosphorylation of DNMT3A was found to be
required for its localization to heterochromatin and cap-
able of shaping the CpG methylome [49]. Phosphorylated
DAXX was reported to facilitate DNA damage-induced
p53 activation [50]. Thus, it seems evident that phosphor-
ylation is very important to these proteins’ normal func-
tions. In some epigenetic regulators, phosphorylation is
associated with cancer cell malignant growth. It will be
interesting to explore the functional links between those
specific phosphorylation events and the epigenetic regula-
tors’ activities in cervical cancer.
Although the chromatin modification pathway was
predominantly mutated across all clinical stages, others,
such as the RAS, PI3K, NOTCH and apoptosis pathways,
were also recurrently mutated at certain stages. These
pathways and the recurrently mutated genes involved
therein, such as EP300, ARID1A, FBXW7, NFE2L2,
PIK3CA, and ERBB2, were all found to be pathogenic in
previous cervical cancer studies [11, 12]. However, only
mutations in ERBB2 were associated with worse survival.
ERBB2 is involved in both the RAS and PI3K pathways.
MAP2K1 and MAP3K1 were also mutated in the RAS
pathway. Thus, the signal cascade, which should be acti-
vated when normally phosphorylated, may be disrupted.
We observed that the mutations in some epigenetic
regulators occurred around the phosphorylation sites.
Currently, the temporal mutational order relationship
or the association between these genetic events is un-
known. The genetic mutations appear to have disrupted
phosphorylation, which could together lead to a series
of disorders in the cervical cancer cells.
One previous study of 115 cervical cancer samples
from Norway and Mexico identified previously unknown
somatic mutations that recurrently occurred in EP300,
FBXW7, NFE2L2, TP53, and ERBB2 [11]. Another study
in 15 cervical cancer patients from Hong Kong revealed
frequently altered genes, including FAT1, ARID1A,
ERBB2, and PIK3CA [51]. One recent study of 228 cer-
vical cancers using TCGA data identified SHKBP1,
ERBB3, CASP8, HLA-A, and TGFBR2 as novel signifi-
cantly mutated genes, and previously identified pathogenic
genes including PIK3CA, EP300, ARID1A, and NFE2L2
were also confirmed [52]. Similarly, all of these genes were
identified in each study using the same approach of ana-
lyzing the significantly mutated genes, whereas we only fo-
cused on the driver genes and core pathways that play
significant roles in tumorigenesis. Some of the gene muta-
tions reported in our study, such as MLL3 and MLL2,
were not previously identified in those studies, which may
be because they did not satisfy the significance criteria. In
contrast, other altered genes in this study, including
EP300, ARID1A, FBXW7, NFE2L2, PIK3CA, and ERBB2,
were reported as pathogenic genes in the aforementioned
previous studies and were consistent with those cervical
cancer genome studies. Interestingly, CASP8, which was
newly identified as a significantly mutated gene in the re-
cent study [52], was also included in the 138 driver genes
in our study, and was frequently mutated in the apoptosis
pathway which was significantly altered at Stage III (Fig. 1;
Additional file 6: Figure S3). Additionally, unlike this
study, other cervical cancer genome studies did not report
the chromatin modification pathway as being predomin-
ately mutated as compared to other core cancer pathways.
Among the genes involved in this pathway, we found that
the mutations in MLL2 were associated with poor survival
in cervical cancer. The role of epigenetic regulator muta-
tions has been identified as increasingly important in
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other cancers’ tumorigenesis [19, 53]; however, it has not
been extensively explored in cervical cancer. This study is
the first to highlight mutations in the epigenetic regula-
tors, particularly the emerging role of MLL2 in cervical
carcinogenesis. Our results shed more light on the epigen-
etic mechanism underlying cervical cancer pathogenesis.
Most epigenetic therapy agents used in treatment are
analogue inhibitors [35]. Clinical studies, however, have
demonstrated their limitations, such as poor activity
against solid tumors and toxicity [35, 54]. Thus, the
merits of this targeted therapy have not yet been estab-
lished. Accordingly, it is imperative that possible therapy
strategies be identified, and the evidence increasingly
suggests that T cells can provide clinical responses by
recognizing unique neo-antigens expressed by somatic
mutations in tumors [55–57]. By screening tumor-
specific neo-antigens and identifying mutation-specific T
cells, the immune targeting of cancer mutations has
demonstrated therapeutic potential [30, 58]. The numer-
ous neo-epitopes in our data derived from the mutations
indicate that an anti-mutation T cell response might be
feasible. Further investigation into potential immuno-
therapies for cervical cancer is warranted.
Conclusions
The role of epigenetic regulator mutations in the tumori-
genesis of other cancers has been recently highlighted
[19, 53]. The association, however, between mutated
epigenetic regulators and cervical carcinogenesis has
not been extensively explored. To our knowledge, this
is the first report to focus on mutations in the epigen-
etic regulators, particularly the central role of MLL2 in
the pathogenesis of cervical cancer on a genome-wide
scale. Our results are important both for understanding
cervical cancer development and for the continued
search for possible therapy strategies.
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Additional file 5: Table S3. Mutated driver genes and variants in patients.
(XLS 99 kb)
Additional file 6: Figure S3. Mutated genes involved in the PI3K, RAS,
apoptosis, and NOTCH pathways. The heatmaps show the distribution of
the mutated genes involved in the four pathways across all clinical
stages. Each column represents an individual, and each row denotes a
gene. The bar graph on the top shows the patients’ subgroup at Stage I,
Stage II, Stage III, and Stage IV as red, blue, orange, and purple, respectively.
(EPS 2420 kb)
Additional file 7: Figure S4. Another 8 epigenetic regulators harboring
mutations destroying phosphorylation sites. The 8 epigenetic regulators
are shown in the context of protein domain models derived from UniProt.
Each filled circle represents a mutated patient. Somatic mutations destroying
the phosphorylation sites are marked in red. Domains are depicted with
various colors. (EPS 1080 kb)
Additional file 8: Table S4. Details of the 25 missense mutations
destroying phosphorylation sites. (XLS 26 kb)
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